Home Real-Time RT-PCR for the Measurement of Prostate-Specific Antigen mRNA Expression in Benign Hyperplasia and Adenocarcinoma of Prostate
Article
Licensed
Unlicensed Requires Authentication

Real-Time RT-PCR for the Measurement of Prostate-Specific Antigen mRNA Expression in Benign Hyperplasia and Adenocarcinoma of Prostate

  • Stefania Gelmini , Carmela Tricarico , Luisa Petrone , Gianni Forti , Andrea Amorosi , Giovanni L. Dedola , Mario Serio , Mario Pazzagli and Claudio Orlando
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 41 Issue 3

Abstract

Since PSA is supposed to play an active role in the progression of prostate cancer, we applied a quantitative RT-PCR to measure the absolute levels of prostate-specific antigen (PSA) mRNA expression in benign and malignant prostatic tissue. Consecutive fine needle prostate biopsy material from 59 patients (43 with prostate adenocarcinoma and 16 with benign prostatic hyperptrophy; BPH) was used for the measurement of PSA mRNA expression. In addition, we evaluated the correlation between PSA synthesis and PSA circulating levels in the same patients. The relationship between PSA mRNA expression and histological grade was also evaluated. PSA mRNA was measured with a quantitative RT-PCR, based on the use of fluorogenic probes, according to the TaqMan reaction system. The mRNA expression for PSA in prostate adenocarcinoma biopsies was highly variable, ranging from 2×104 to 2.1×108 molecules/μg total RNA with a mean value of 2.5×107 and significantly higher (p = 0.006) than that found in BPH patients (mean: 1.3×106 and range: 6.9×102 to 8×106). The mRNA PSA expression in needle biopsy material did not seem to be related to PSA circulating levels in prostate cancer patients (r = 0.281), whereas in BPH patients the two parameters correlated significantly (r = 0.667, p < 0.01). A reduction of PSA mRNA expression in samples with a lower grade of differentiation (Gleason score 9–10) was also observed.

Even though a mean increase of PSA expression was demonstrated in cancer samples, this small difference does not confirm a significant role of PSA proteolytic activity in prostate cancer progression. In conclusion, the assay procedure we proposed represents a reliable basis for more extensive study of PSA physiopathology in prostate cancer.

:
Published Online: 2005-06-01
Published in Print: 2003-03-24

Copyright © 2003 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. 3rd Conference on Hyperhomocysteinemia Saarbrücken, Germany, 11–12 April 2003, Saarland University
  2. Platelet Receptors and Their Role in Diseases
  3. Real-Time RT-PCR for the Measurement of Prostate-Specific Antigen mRNA Expression in Benign Hyperplasia and Adenocarcinoma of Prostate
  4. Detection of a Novel Exon 4 Low-Density Lipoprotein Receptor Gene Deletion in a Swiss Family with Severe Familial Hypercholesterolemia
  5. Absence of Known Familial Hemiplegic Migraine (FHM) Mutations in the CACNA1A Gene in Patients with common Migraine: Implications for Genetic Testing
  6. Association between 5,10-Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphisms and Conotruncal Heart Defects
  7. Rapid and Reliable Genotyping of the C181T Polymorphism in the Bradykinin B2 Receptor Gene
  8. Steroids, Sex Hormone-Binding Globulin, Homocysteine, Selected Hormones and Markers of Lipid and Carbohydrate Metabolism in Patients with Severe Hypothyroidism and Their Changes Following Thyroid Hormone Supplementation
  9. Anaerobic Bacteremia: The Yield of Positive Anaerobic Blood Cultures: Patient Characteristics and Potential Risk Factors
  10. Genotyping of Alcohol Dehydrogenase Type 2 and 3 Using a Two-Buffer Polyacrylamide Gel Electrophoresis System
  11. Effect of Partial Proteolysis on the Activation Energy of β-N-Acetylhexosaminidase Precursor and Mature Forms
  12. Angiogenin and Gestational Trophoblastic Tumors, a Promising Prognostic Marker
  13. Carbohydrate 19-9 Antigen Is Not a Marker of Liver Disease in Patients with Cystic Fibrosis
  14. Assay Using Succinyldithiocholine as Substrate: The Method of Choice for the Measurement of Cholinesterase Catalytic Activity in Serum to Diagnose Succinyldicholine Sensitivity
  15. National External Quality Assessment Scheme for Lymphocyte Immunophenotyping in Belgium
  16. Quality Assurance for Cerebrospinal Fluid Protein Analysis: International Consensus by an Internet-Based Group Discussion
  17. Guidelines for the Analysis of Bence Jones Protein
  18. Discordance Rate, a New Concept for Combining Diagnostic Decisions with Analytical Performance Characteristics. 1. Application in Method or Sample System Comparisons and in Defining Decision Limits
  19. Urinary Homogentisic Acid in Alkaptonuric and Healthy Children
  20. The Influence of Hemolysis, Turbidity and Icterus on the Measurements of CK-MB, Troponin I and Myoglobin
  21. Evaluation of Cobas Integra® 800 under Simulated Routine Conditions in Six Laboratories
  22. Guidelines for the Laboratory Investigation of Inherited Thrombophilias. Recommendations for the First Level Clinical Laboratories
  23. Detection of PvuII Polymorphism within Intron 1 of ESR1 Gene by Real-Time PCR
  24. Meetings and Awards
Downloaded on 24.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2003.040/html
Scroll to top button